Avalo Therapeutics, Inc. (AVTX) stock
AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.76+0.06 (+0.78%)
Close on Nov 13, 2026Market cap $416.17MP/E –Yield –
Avalo Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Avalo Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$95.49M. For fiscal 2025 it was -$72.58M. The highest annual figure on record is $14.32M in fiscal 2017.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$72.58M | – |
| FY2024 | Dec 31, 2024 | -$68.34M | – |
| FY2023 | Dec 31, 2023 | -$27.19M | – |
| FY2022 | Dec 31, 2022 | -$37.27M | – |
| FY2021 | Dec 31, 2021 | -$80.48M | – |
| FY2020 | Dec 31, 2020 | -$71.00M | – |
| FY2019 | Dec 31, 2019 | -$12.25M | – |
| FY2018 | Dec 31, 2018 | -$30.82M | -315.3% |
| FY2017 | Dec 31, 2017 | $14.32M | – |
| FY2016 | Dec 31, 2016 | -$16.05M | – |
| FY2015 | Dec 31, 2015 | -$10.99M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$23.38M | – |
| Q2 FY2026 | Jun 30, 2026 | -$31.50M | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.88M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.73M | – |
| Q3 FY2025 | Sep 30, 2025 | -$19.14M | – |
| Q2 FY2025 | Jun 30, 2025 | -$19.18M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.53M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.24M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.83M | – |
| Q2 FY2024 | Jun 30, 2024 | -$9.54M | – |
| Q1 FY2024 | Mar 31, 2024 | -$32.73M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.62M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.71M | -189.8% |
| Q2 FY2023 | Jun 30, 2023 | -$7.11M | – |
| Q1 FY2023 | Mar 31, 2023 | -$8.76M | – |
| Q4 FY2022 | Dec 31, 2022 | -$8.82M | – |
| Q3 FY2022 | Sep 30, 2022 | $4.13M | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.80M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.79M | – |
| Q4 FY2021 | Dec 31, 2021 | -$17.67M | – |
| Q3 FY2021 | Sep 30, 2021 | -$16.01M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.67M | – |
| Q1 FY2021 | Mar 31, 2021 | -$30.13M | – |
| Q4 FY2020 | Dec 31, 2020 | -$15.80M | – |
| Q3 FY2020 | Sep 30, 2020 | -$12.85M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.39M | – |
| Q1 FY2020 | Mar 31, 2020 | -$30.96M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.11M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.80M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.44M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.91M | – |
| Q4 FY2018 | Dec 31, 2018 | -$336.47K | – |
| Q3 FY2018 | Sep 30, 2018 | -$23.24M | -206.0% |
| Q2 FY2018 | Jun 30, 2018 | -$4.51M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.73M | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.95M | – |
| Q3 FY2017 | Sep 30, 2017 | $21.93M | – |
| Q2 FY2017 | Jun 30, 2017 | -$1.77M | – |
| Q1 FY2017 | Mar 31, 2017 | -$1.89M | – |
See a number that looks wrong?